BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bedford Laboratories Initiates Voluntary Recall of Indomethacin for Injection


6/14/2011 10:09:09 AM

BEDFORD, Ohio, June 13, 2011 /PRNewswire/ -- On April 19, 2011, Bedford Laboratories, a division of Ben Venue Laboratories, Inc., initiated a nationwide voluntary recall of the following product:

(Logo: http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO )

Indomethacin for Injection, USP, 1mg Single Dose Vial

NDC #55390-299-01, Lot 1948138, Exp. Date September 2011

PLEASE NOTE: This recall is for Lot 1948138 Only. No other lots of Indomethacin for Injection, USP are subject to this voluntary recall.

This voluntary recall was initiated because some of the vials of lot number 1948138 may contain particulate matter. Out-of-specification results were obtained for Lot 1948138 for particulate matter >/= 10 micron. The product did meet specification for particulate matter >/= 25 micron. The particulate matter has been identified as active drug substance and not foreign material or contamination. Indomethacin for injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants, who typically have small blood vessels. FDA has stated that particulate matter may provoke an immune reaction and/or lead to microinfarcts which could be serious and life threatening.

The product was distributed to wholesalers and distributors nationwide.

Hospitals, emergency rooms, clinics, physician offices and other healthcare facilities and providers should not use Bedford Laboratories' Indomethacin Injection, USP 1mg Vials, with Lot 1948138, for patient care and should immediately quarantine any product for return.

On April 19, 2011, Bedford Laboratories notified its wholesalers and distributors by email, facsimile and/or overnight courier and arranged for return of all recalled product. Should consumers/distributors/retailers still have product which is being recalled, they should stop use and contact Bedford Laboratories Customer Service.

Bedford Laboratories will credit accounts for all returned product with lot 1948138. Those with questions about the return or recall process, please call our Customer Service Department at 1.800.562.4797: Monday Friday from 8:00 am to 5:30 pm or by email at Indomethacinrecall1948138.cle@boehringer-ingelheim.com.

Hospitals, emergency rooms, clinics, physician offices and other healthcare facilities and providers, or patients with product quality compliance, medical or other questions concerning the use of the product or reasons for this recall should contact the Professional Services Department at 1.800.521.5169.

Any adverse reactions experienced with the use of this product should be reported to Bedford Laboratories at 1.800.521.5169.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, or regular mail or by fax.


Bedford Laboratories has informed the FDA of its actions and is maintaining ongoing discussion with the agency. This voluntary recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

As is standard practice, and as stated in the Product Package Insert, "Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."

Indomethacin for Injection, USP is manufactured by Ben Venue Laboratories, Inc. and is distributed by Bedford Laboratories.

About Bedford Laboratories

Bedford Laboratories is located in Bedford, OH and began in 1993 as a division of Ben Venue Laboratories. Bedford Laboratories supplies an extensive selection of critical-care and medically necessary multisource and specialty injectable products to the healthcare marketplace. For more information, please visit http://www.BedfordLabs.com.

About Ben Venue Laboratories, Inc.

Ben Venue Laboratories, Inc. was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. Ben Venue is located in Bedford, Ohio and employs more than 1,300 people. For more information, visit www.benvenue.com.

Ben Venue is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies. Please visit http://us.boehringer-ingelheim.com.

SOURCE Bedford Laboratories



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->